Breaking News, Collaborations & Alliances

BioCentriq and Kytopen Enter Cell Therapy Partnership

To show the impact to autologous and allogeneic cell therapies by integrating novel transfection technology with other steps in the manufacturing process.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioCentriq, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, has entered a partnership with Kytopen, a Cambridge, MA-based startup spun out of Massachusetts Institute of Technology (MIT).   “Our mission at BioCentriq is to work with innovative industry partners like Kytopen to advance the production and manufacturing of cell and gene therapies, making them accessible and affordable for the patients who so desperately need them,” said Haro Hartouni...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters